
09/02/2025
I am very pleased with our recent publication in ๐ฆ๐๐๐ก ๐๐ผ๐๐ฟ๐ป๐ฎ๐น ๐ผ๐ณ ๐๐๐๐ฒ๐ป๐ฒ๐ผ๐๐ ๐ ๐ฒ๐ฑ๐ถ๐ฐ๐ถ๐ป๐ฒ. This article overviews reports of counterfeit botulinum toxin and the risk of cosmetic iatrogenic botulism (CIB). We looked at reports of CIB linked to procedures carried out by unlicensed or untrained individuals or involving counterfeit botulinum toxin products. We highlight the regulatory gaps that may contribute to unsafe practices in this area. There is an urgent need for unified national regulations in the United States, along with global standards, to clearly define who is authorized to perform these procedures and under what conditions they can do so. Furthermore, it is essential to enhance enforcement measures and increase public awareness to protect patients and uphold the highest safety standards.
I am very happy with the essential contributions of and .
Stay tuned, more to come!